| human | Q5 |
| P496 | ORCID iD | 0000-0002-5183-7818 |
| P1053 | ResearcherID | K-9458-2016 |
| P69 | educated at | University of Pavia | Q219317 |
| Department of Mathematics "Federigo Enriques" | Q67146961 | ||
| P108 | employer | Luigi Sacco Hospital | Q3886605 |
| P735 | given name | Giuliano | Q9496769 |
| Giuliano | Q9496769 | ||
| P106 | occupation | researcher | Q1650915 |
| Q34341541 | 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience |
| Q42989245 | A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy |
| Q90756968 | An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents |
| Q57997331 | Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals |
| Q34273315 | Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service |
| Q58812142 | Cholesterol levels in HIV–HCV infected patients treated with lopinavir/r: Results from the SCOLTA project |
| Q91192779 | Choosing appropriate pharmacotherapy for drug-resistant HIV |
| Q85015733 | Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients |
| Q36396149 | Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing |
| Q42207795 | Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study |
| Q49877121 | Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World. |
| Q33878754 | Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients |
| Q34608823 | Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world |
| Q40652183 | Determinants of bone diseases in tenofovir-treated HIV patients. |
| Q36628396 | Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy |
| Q40079937 | Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV-infected patients with virological suppression |
| Q91294339 | Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment |
| Q42247735 | Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting |
| Q98294984 | Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study |
| Q36452414 | Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis |
| Q41993024 | Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF. |
| Q40282068 | Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference |
| Q98473116 | Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study) |
| Q30710478 | Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. |
| Q47831901 | Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals |
| Q36234850 | HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy |
| Q41579095 | Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome |
| Q40361742 | How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life? |
| Q41932770 | Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders |
| Q53310922 | Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. |
| Q33703634 | Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens |
| Q58580724 | Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS |
| Q59306868 | Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons |
| Q59306861 | Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 |
| Q28477797 | KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy |
| Q38563634 | Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology |
| Q86550504 | Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections |
| Q28535587 | Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events |
| Q56394656 | Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment |
| Q28546430 | Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? |
| Q38972180 | Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies |
| Q58812114 | Negative Influence of HIV Infection on Day-Night Blood Pressure Variability |
| Q35741765 | New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy) |
| Q39222831 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program |
| Q39501143 | Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group |
| Q91021077 | Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV |
| Q41717288 | Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients |
| Q55379857 | Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. |
| Q57997347 | Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis |
| Q31110946 | Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort |
| Q42992579 | Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals |
| Q44314941 | Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy |
| Q90675452 | Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study |
| Q35694729 | Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing |
| Q28552719 | Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort |
| Q56334610 | The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection |
| Q43911880 | The cost of HIV disease in Northern Italy: the payer's perspective |
| Q34558508 | The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing |
| Q30869874 | Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort |
| Q45284793 | Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness |
| Q46839281 | Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study |
Search more.